Rx Statin Critic Predicts Safer Use In Lower-Dose Switch OTCs
This article was originally published in The Tan Sheet
Executive Summary
Duane Graveline says drug firms “are going to realize” they will not “get any support from people who understand” the full range of statin adverse effects. “Tens of thousands of statin users” report weakness, instability, easy fatigue, muscle aches and pains, depression, personality change and faulty memory, he says.
You may also be interested in...
Room For Innovative Switches Could Lurk In Existing FDA Framework
When firms suggest submitting switch NDAs for “something that would be worth engaging on, we’re not going to tell you no,” says FDA nonprescription drug program chief Theresa Michele.
Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation
Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.